Effects of bariatric surgery on HDL structure and functionality: results from a prospective trial

Evangelia Zvintzou1, George Skroubis2, Angelika Chroni3

  • 1Department of Pharmacology, University of Patras, School of Medicine, Rio Achaias, Greece.

Insights

Rapid weight loss from bariatric surgery significantly improves high-density lipoprotein (HDL) quality and antioxidant function. This enhanced HDL structure may explain the cardiovascular benefits observed after malabsorptive procedures.

Area of Science:

  • Cardiovascular Science
  • Metabolic Health
  • Bariatric Surgery Research

Background:

  • High-density lipoprotein cholesterol (HDL-C) levels and quality are crucial for preventing atherosclerosis.
  • Obesity and metabolic syndrome are linked to reduced HDL-C and increased coronary heart disease risk.
  • The impact of weight loss on HDL quality and function remains understudied.

Purpose of the Study:

  • To examine the effects of rapid weight loss on HDL structure and antioxidant capacity.
  • To investigate HDL changes in patients undergoing malabsorptive bariatric procedures.

Main Methods:

  • Collected plasma samples from 20 morbidly obese patients (BMI >50) before and 6 months after bariatric surgery.
  • Isolated and analyzed high-density lipoprotein (HDL) using biochemical techniques.

Main Results:

  • Observed significant alterations in HDL apolipoprotein ratios, increased mature HDL subspecies, and enhanced HDL antioxidant potential.
  • Identified two patient subgroups based on pre-surgery HDL composition (apoA-I, apoCIII, apoE).
  • Demonstrated a post-surgery shift from apoE- to apoA-I-containing HDL particles in both subgroups.

Conclusions:

  • Rapid weight loss via malabsorptive bariatric procedures substantially improves HDL structure and functionality.
  • These HDL improvements may contribute to the cardiovascular health benefits of bariatric surgery.
Abstract

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
437
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324